Get the Stockscreener App
0.2404
13.57%
-0.1796
Avenue Therapeutics Inc stock is traded at $0.2404, with a volume of 606.
It is down -13.57% in the last 24 hours and down -70.96% over the past month.
See More
Previous Close:
$0.42
Open:
$0.2404
24h Volume:
606
Relative Volume:
4.91
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.0631
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
-13.57%
1M Performance:
-70.96%
6M Performance:
-83.79%
1Y Performance:
-96.88%
1-Day Range:
$0.2404
$0.2404
1-Week Range:
$0.2404
$0.2404
52-Week Range:
$0.2404
$0.2404
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.2404 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
656 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Park Avenue Securities LLC - Defense World
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Park Avenue Securities LLC Invests $259,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Park Avenue Securities LLC - Defense World
Yousif Capital Management LLC Has $1.99 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 156.3% in May - Defense World
Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World
NBC Securities Inc. Takes $31,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Cut to Sell at Wall Street Zen - Defense World
Park Avenue Securities LLC Has $713,000 Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Rhumbline Advisers Reduces Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Autolus Therapeutics’ (AUTL) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Park Avenue Securities LLC Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
NBC Securities Inc. Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World
Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Jane Street Group LLC Sells 44,603 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Nuveen Asset Management LLC Raises Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Jane Street Group LLC Increases Stock Holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Defense World
Public Employees Retirement System of Ohio Invests $137,000 in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms - The Daily Jeffersonian
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fortress Biotech, Inc. of Class Action Lawsuit and Upcoming Deadline – FBIO - ACCESS Newswire
BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World
37,984 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Acquired by D. E. Shaw & Co. Inc. - Defense World
D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Holdings Increased by Northern Trust Corp - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen - Defense World
AJ201 shows good safety, hints of efficacy in SBMA clinical trial - SMA News Today
Annji Pharmaceutical Company Announces Positive Phase 1/2A Results for Aj201 in Spinal and Bulbar Muscular Atrophy Patients - marketscreener.com
NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 - The Globe and Mail
StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World
Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World
Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN
Avenue Therapeutics Ends License Agreement with AnnJi - TipRanks
Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 - StreetInsider
Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider
Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews
CBLI Back On Track, HTBX Joins Hands With OncoSec, PRAH In Good Health - RTTNews
Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com
SEC Form POS AM filed by Fortress Biotech Inc. - Quantisnow
AVENUE THERAPEUTICS, INC. SEC 10-K Report - TradingView
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan
Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI - The Manila Times
Oncotelic Therapeutics Publishes New Research Demonstrating - GlobeNewswire
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Cap:
|
Volume (24h):